Clinical Lipidology

A Companion to Braunwald's Heart Disease

AvChristie M. Ballantyne

Inbunden, Engelska, 2023

Del i serien Companion to Braunwald's Heart Disease

1 636 kr

Beställningsvara. Skickas inom 5-8 vardagar. Fri frakt över 249 kr.

Beskrivning

Part of the renowned Braunwald family of references, Clinical Lipidology: A Companion to Braunwald’s Heart Disease provides today’s clinicians with clear, authoritative guidance on the therapeutic management of patients with high cholesterol levels and other atherogenic lipid disorders. An invaluable resource for cardiologists, lipidologists, endocrinologists, and internal medicine physicians, this one-stop reference covers everything from basic science and the pathogenesis of atherothrombotic disease to risk assessment and the latest therapy options. Now fully updated from cover to cover, the 3rd Edition offers unparalleled coverage of lipidology in an accessible and user-friendly manner.

Produktinformation

Utgivningsdatum:2023-02-16
Mått:216 x 276 x 22 mm
Vikt:1 430 g
Format:Inbunden
Språk:Engelska
Serie:Companion to Braunwald's Heart Disease
Antal sidor:432
Upplaga:3
Förlag:Elsevier Health Sciences
ISBN:9780323882866

Utforska kategorier

Hjärt- och kärlsjukdomar inom Medicin

Recensioner i media

Select Guide Rating

Innehållsförteckning

SECTION I INTRODUCTION/BASIC MECHANISMS1. Overview of Lipids and AtherosclerosisSECTION II RISK ASSESSMENT2. Overview of Risk Assessment3. Measurement of Low- Density Lipoprotein Cholesterol, Non-High- Density Lipoprotein Cholesterol, Apolipoprotein B, and Low- Density Lipoprotein Particle Concentration4. Triglycerides, Triglyceride- Rich Lipoproteins, and High- Density Lipoprotein in Coronary Heart Disease Risk Assessment5. Lipoprotein(a) in Cardiovascular Risk Assessment6. Clinical Evaluation for Genetic Testing and Secondary Causes of Dyslipidemia7. Polygenic Risk Scores8. High- Sensitivity C- Reactive Protein9. Emerging Assays for Risk Assessment10. Imaging Atherosclerosis for Risk Stratifi cation: Cardiac Computed Tomography and Carotid UltrasoundSECTION III THERAPY11. Overview of General Approach to Management of Dyslipidemias12. Treatment Guidelines Overview: American Heart Association/American College of Cardiology/Multisociety Guideline and Updates13. Treatment Guidelines Overview: European Society of Cardiology/European Atherosclerosis Society Guidelines14. Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease15. Updated Clinical Guide to Exercise and Lipids16. Obesity, Lipids, and Cardiovascular Disease17. Statins18. Cholesterol Absorption Inhibitors19. Omega- 3 Fatty Acids20. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition21. Inclisiran22. Bempedoic Acid23. Pemafi brate: A New Selective Peroxisome Proliferator-Activated Receptor-_Modulator for Hypertriglyceridemia Management24. Anti- inflammatory Therapy for Cardiovascular Disease25. Nutraceuticals and Functional Foods for Cholesterol ReductionSECTION IV NEW AND EVOLVING THERAPEUTIC TARGETS AND PLATFORMS26. Evolving Therapeutic Targets: Lipoprotein(a)27. Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias28. Evolving Therapeutic Targets: Apolipoprotein C- III29. Evolving Therapeutic Targets: Cholesteryl Ester Transfer Protein Inhibition30. Gene Therapy and Therapeutic Genome Editing in Liver for Lipid DisordersSECTION V SPECIAL PATIENT POPULATIONS31. Special Patient Populations: Diabetes and Metabolic Syndrome32. Special Patient Populations: Women and Older Adults33. Special Patient Populations: Children and Adolescents34. Special Patient Populations: Familial Hypercholesterolemia and Other Severe Hypercholesterolemias35. Special Patient Populations: Treatment of Familial Chylomicronemia Syndrome and Sustained Chylomicronemia36. Special Patient Populations: Acute Coronary Syndromes37. Special Patient Populations: Transplant Recipients38. Special Populations: Chronic Kidney Disease39. Special Patient Populations: Lipid Abnormalities in High- Risk Racial/Ethnic Groups40. Persons With Human Immunodeficiency Virus